Video

Treatment Strategies and Patient Specific Factors in AML

Transcript:

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Katherine L. Nathanson, MD
Julie M. Vose, MD, MBA
Dr Garrido-Laguna on the Safety of Daraxonrasib in KRAS G12X–Mutated PDAC
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Aditya Bardia, MD, MPH, FASCO
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Jin-Ji Yang, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Carrie L. Kitko, MD
Related Content
Multiple Myeloma | Image Credit: © Свет Лана – stock.adobe.com
March 12th 2025

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

MT-8421 in Advanced Solid Tumors | Image Credit: © Cornflakesei – stock.adobe.com
March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Cema-Cel in R/R LBCL | Image Credit: © LASZLO – stock.adobe.com
March 11th 2025

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

Lung cancer Image credit: catalin – stock.adobe.com
March 10th 2025

Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC